The Latest Cardiac and Vascular News
CARY, N.C. and BASEL, Switzerland, Sept. 13, 2021 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented an e-poster at the European Respiratory Society annual congress highlighting the protocol and design of the ongoing double-blind, placebo-controlled ELEVATE 2 (NCI NCT04712669) Phase 2b study of rodatristat ethyl (rodatristat) in patients […]
CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company’s lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic […]
Cary, N.C. and Basel, Switzerland, May 06, 2021 (GLOBE NEWSWIRE) — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company has initiated its ELEVATE 2 Study, a Phase 2b clinical trial of its lead product candidate, rodatristat ethyl (“rodatristat”), for the […]
